Avalo Therapeutics (AVTX) Liabilities and Shareholders Equity (2014 - 2026)

Avalo Therapeutics' Liabilities and Shareholders Equity history runs 13 years deep, the most recent figure standing at $99.9 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 27.89% year-over-year to $99.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $468.0 million (down 5.64% YoY) and the FY2025 annual result came in at $116.5 million, down 22.74% from the prior year.
• Liabilities and Shareholders Equity was $99.9 million for Q1 2026 at Avalo Therapeutics, down from $116.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $150.7 million in Q4 2024 and bottomed at $21.0 million in Q4 2023.
• A 5-year average of $80.1 million and a median of $98.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity tumbled 61.67% — and 2024, when it surged 618.01%.
• Avalo Therapeutics' Liabilities and Shareholders Equity stood at $33.4 million in 2022, then tumbled by 37.08% to $21.0 million in 2023, then jumped by 618.01% to $150.7 million in 2024, then declined by 22.74% to $116.5 million in 2025, then decreased by 14.23% to $99.9 million in 2026.
• Business Quant data shows AVTX's Liabilities and Shareholders Equity at $99.9 million in Q1 2026, $116.5 million in Q4 2025, and $125.1 million in Q3 2025.